ArticleCombinatorial chemistry & high throughput screening2025
Mechanisms of QiShenYiQi in Inhibiting Blood-Brain Barrier Damage Following Stroke: A Network Pharmacology and Experimental Study.
Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
background and purposeQiShenYiQi (QSYQ) has shown promise in the treatment of blood-brain barrier (BBB) damage following stroke. However, the identification of its bioactive components and the underlying molecular mechanisms of action remain unknown. This study aimed to investigate the active ingredients and mechanisms involved in the inhibitory effects of QSYQ on BBB damage after ischemic stroke based on network pharmacology and experimental verification. MATERIALS AND
methodsThe chemical composition and target information of QSYQ were obtained from the Traditional Chinese Medicine Systems Pharmacology and Analysis Platform. BBB injury-related targets were identified by screening databases, and the overlapping targets with QSYQ were collected. Cytoscape software was utilized to construct protein-protein interaction (PPI) networks. Molecular docking analysis was conducted using AutoDock software. Animal experiments were carried out to verify the protective effect of QSYQ on BBB and explore potential molecular mechanisms.
resultsA total of 131 active ingredients in QSYQ and 154 common targets related to QSYQ and BBB damage were identified. Analysis of the PPI network revealed key targets including ALB, INS, ACTB, TP53, and CASP3 against BBB injury. Molecular docking analysis indicated favorable binding interactions between dihydrotanshinlactone, tanshinone IIA, salviolone, and their respective target proteins, such as FOS, INS, CASP3, and JUN. In animal experiments, QSYQ demonstrated effective inhibition of BBB damage, and this effect may be attributed to the regulation of ALB, INS, TP53, and CASP3.
conclusionThis study provides intriguing insights into the mechanisms by which QSYQ protects against BBB injury following ischemic stroke. Key targets, including ALB, INS, TP53, and CASP3, could be potentially involved in the beneficial effects of QSYQ.
Indexed as
Identifiers
38847173What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.